GoodRx (NASDAQ:GDRX) PT Lowered to $7.00 at Deutsche Bank Aktiengesellschaft

GoodRx (NASDAQ:GDRXGet Rating) had its price target trimmed by Deutsche Bank Aktiengesellschaft from $9.00 to $7.00 in a research note released on Thursday, The Fly reports.

A number of other brokerages have also recently issued reports on GDRX. JPMorgan Chase & Co. upgraded shares of GoodRx from an underweight rating to a neutral rating and dropped their price target for the stock from $10.00 to $8.00 in a research note on Friday, November 4th. The Goldman Sachs Group lowered their target price on shares of GoodRx from $10.00 to $8.00 and set a neutral rating on the stock in a research note on Wednesday, November 9th. Royal Bank of Canada lowered their target price on shares of GoodRx from $11.00 to $6.00 and set a sector perform rating on the stock in a research note on Wednesday, November 9th. Credit Suisse Group upped their target price on shares of GoodRx from $10.00 to $11.00 and gave the company a neutral rating in a research note on Tuesday, August 9th. Finally, SVB Leerink upped their target price on shares of GoodRx from $8.00 to $11.00 and gave the company a market perform rating in a research note on Tuesday, August 9th. Fifteen research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $13.58.

GoodRx Stock Performance

Shares of GoodRx stock opened at $5.71 on Thursday. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -33.59, a PEG ratio of 18.52 and a beta of 0.98. The firm’s 50-day moving average is $5.28 and its 200 day moving average is $6.67. GoodRx has a 1 year low of $3.82 and a 1 year high of $43.00. The company has a debt-to-equity ratio of 0.80, a current ratio of 11.23 and a quick ratio of 11.23.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently added to or reduced their stakes in GDRX. CWM LLC boosted its position in shares of GoodRx by 50.2% during the 1st quarter. CWM LLC now owns 2,224 shares of the company’s stock valued at $43,000 after acquiring an additional 743 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of GoodRx by 1,233.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 5,066 shares of the company’s stock valued at $30,000 after acquiring an additional 4,686 shares during the last quarter. Levin Capital Strategies L.P. bought a new position in shares of GoodRx during the 3rd quarter valued at approximately $47,000. Victory Capital Management Inc. bought a new position in shares of GoodRx during the 2nd quarter valued at approximately $59,000. Finally, Apollon Wealth Management LLC bought a new position in shares of GoodRx during the 2nd quarter valued at approximately $60,000. 39.16% of the stock is owned by hedge funds and other institutional investors.

About GoodRx

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Articles

The Fly logo

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.